Prostate Cancer Metastatic
Conditions
Brief summary
The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in those patients who have progressed during or after docetaxel and to document the overall safety of cabazitaxel in these patients. Please note that in each country, patient recruitment will end when cabazitaxel becomes commercially available.
Interventions
DRUGCABAZITAXEL
Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
Sponsors
Sanofi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Metastatic Hormone Refractory Prostate Cancer (mHRPC) previously treated with a docetaxel-containing regimen * Disease Progression during or after docetaxel-containing regimen for mHRPC * Surgical or medical castration * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2 * Life-expectancy ≥3 months * Adequate bone marrow, liver, and renal function: Neutrophils\> 1500 /mm3; Hemoglobin \> 10 g/dL; Platelets \> 100 x109/L; Bilirubin \< ULN; SGOT (AST) \< 1.5xULN; SGPT (ALT) \< 1.5xULN; Creatinine \< 1.5xULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \< 60 mL/min should be excluded.
Exclusion criteria
* Prior radiotherapy to ≥ 40% of bone marrow * Prior radionuclide therapy (samarium-153, strontium-89, P-32…) * Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment * Active grade ≥2 peripheral neuropathy * Active grade ≥2 stomatitis * Active infection requiring systemic antibiotic or anti-fungal medication * Active cancer (other than mHRPC) including prior malignancy from which the patient has been disease-free for ≤5 years (except superficial basal cell skin cancer) * Known brain or leptomeningeal involvement * History of severe hypersensitivity reaction (≥grade 3) to docetaxel * History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * History of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone * Uncontrolled severe illness or medical condition (including uncontrolled cardiac arrhythmias, angina pectoris, hypertension or diabetes mellitus). History of congestive heart failure (NYHA III or IV) or myocardial infarction within last 6 months is also not allowed. * Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5 * Participation in a clinical trial with any investigational drug * Patient with reproductive potential not implementing accepted and effective method of contraception The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen | Up to 30 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To document safety of cabazitaxel in these patients | Up to 35 weeks |
Countries
Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, Spain, Sweden, Taiwan, United Kingdom
Outcome results
None listed